BRPI1011940B8 - método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero - Google Patents
método de redobramento de uma proteína expressa em um sistema de expressão de não mamíferoInfo
- Publication number
- BRPI1011940B8 BRPI1011940B8 BRPI1011940A BRPI1011940A BRPI1011940B8 BR PI1011940 B8 BRPI1011940 B8 BR PI1011940B8 BR PI1011940 A BRPI1011940 A BR PI1011940A BR PI1011940 A BRPI1011940 A BR PI1011940A BR PI1011940 B8 BRPI1011940 B8 BR PI1011940B8
- Authority
- BR
- Brazil
- Prior art keywords
- refolding
- expression system
- mammalian expression
- protein expressed
- concentration equal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21925709P | 2009-06-22 | 2009-06-22 | |
| US61/219,257 | 2009-06-22 | ||
| PCT/US2010/039390 WO2011005488A1 (en) | 2009-06-22 | 2010-06-21 | Refolding proteins using a chemically controlled redox state |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1011940A2 BRPI1011940A2 (pt) | 2016-11-22 |
| BRPI1011940B1 BRPI1011940B1 (pt) | 2021-07-20 |
| BRPI1011940B8 true BRPI1011940B8 (pt) | 2021-08-03 |
Family
ID=42710673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011940A BRPI1011940B8 (pt) | 2009-06-22 | 2010-06-21 | método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US8952138B2 (https=) |
| EP (2) | EP3366692A1 (https=) |
| JP (2) | JP5808323B2 (https=) |
| KR (1) | KR101741859B1 (https=) |
| CN (1) | CN102482321B (https=) |
| AU (1) | AU2010270986B2 (https=) |
| BR (1) | BRPI1011940B8 (https=) |
| CA (1) | CA2765881C (https=) |
| CL (1) | CL2011003278A1 (https=) |
| EA (1) | EA020621B1 (https=) |
| IL (1) | IL216954A (https=) |
| MX (1) | MX2011013898A (https=) |
| SG (1) | SG176963A1 (https=) |
| WO (1) | WO2011005488A1 (https=) |
| ZA (1) | ZA201200512B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3366692A1 (en) | 2009-06-22 | 2018-08-29 | Amgen, Inc | Refolding proteins using a chemically controlled redox state |
| AU2010266093B2 (en) | 2009-06-25 | 2013-06-27 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| US20150376228A1 (en) * | 2013-02-22 | 2015-12-31 | Biogenomics Limited | Process for high efficiency refolding of recombinant proteins |
| WO2017019776A1 (en) * | 2015-07-27 | 2017-02-02 | Purdue Research Foundation | Tandem folding methods to improve protein folding yield |
| EP3344651B1 (en) | 2015-09-02 | 2022-03-02 | Merck Sharp & Dohme Corp. | A process for obtaining insulin with correctly formed disulfide bonds |
| KR102579850B1 (ko) * | 2016-07-22 | 2023-09-18 | 암젠 인크 | Fc-함유 단백질의 정제 방법 |
| CN108276470A (zh) * | 2017-01-06 | 2018-07-13 | 深圳市新产业生物医学工程股份有限公司 | 细胞裂解液、提取胞内蛋白的方法、制备弓形虫抗原的方法和试剂盒 |
| CN110494120B (zh) * | 2017-04-10 | 2023-07-18 | 花王株式会社 | 去除角栓的方法 |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| EP4083058A3 (en) * | 2018-11-07 | 2023-01-11 | Applied Molecular Transport Inc. | Delivery constructs for transcytosis and related methods |
| ES3040791T3 (en) | 2020-12-18 | 2025-11-05 | Richter Gedeon Nyrt | Methods for the purification of refolded fc-peptide fusion protein |
| CN115894604B (zh) * | 2022-12-16 | 2024-01-23 | 康日百奥生物科技(苏州)有限公司 | 重组蛋白澄清纯化方法 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4468464A (en) | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| EP0122080B1 (en) | 1983-03-25 | 1989-09-13 | Celltech Limited | A process for the production of a protein |
| US4468454A (en) | 1983-06-10 | 1984-08-28 | E. I. Du Pont De Nemours And Company | Antifoggant process |
| US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| GB8508340D0 (en) | 1985-03-29 | 1985-05-09 | Creighton T E | Production of protein |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| IL86090A (en) | 1987-04-16 | 1993-03-15 | Cetus Oncology Corp | Production of purified, biologically active, bacterially produced recombinant human csf-1 |
| CA1339757C (en) | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
| CA1329119C (en) | 1988-03-29 | 1994-05-03 | Milton David Goldenberg | Cytotoxic therapy |
| GB8807673D0 (en) | 1988-03-31 | 1988-05-05 | Lingner & Fischer Gmbh | Novel article |
| KR0133561B1 (ko) | 1988-05-13 | 1998-04-21 | 스티븐 엠. 오드레 | 과립구 군체 자극인자의 정제방법 |
| GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5986070A (en) | 1990-04-06 | 1999-11-16 | Amgen Inc. | Production of biologically active NGF proteins |
| AU664021B2 (en) * | 1990-09-05 | 1995-11-02 | Natinco Nv | Solubilization of proteins in active forms |
| WO1993018136A1 (en) | 1992-03-05 | 1993-09-16 | Cytomed, Inc. | Process for supporting hematopoietic progenitor cells |
| US5663304A (en) | 1993-08-20 | 1997-09-02 | Genentech, Inc. | Refolding of misfolded insulin-like growth factor-I |
| EP0657466B1 (en) | 1993-11-10 | 1997-01-15 | Pfizer Inc. | A process for refolding of (pro-)chymosin, comprising recycling of urea |
| US5466377A (en) | 1994-01-19 | 1995-11-14 | Grandics; Peter | Chromatography media and their uses |
| IL113497A (en) | 1994-04-28 | 2001-01-11 | Amgen Inc | Method for controlling metallophosphate precipitation in high cell density fermentations |
| AU2603995A (en) * | 1994-05-25 | 1995-12-18 | University Of Nebraska Board Of Regents | Biologically active glycoprotein hormones produced in procaryotic cells |
| AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
| AU729540B2 (en) | 1996-01-23 | 2001-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | Methods for purification and use of erythropoietin binding protein |
| US5935824A (en) | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
| US20020052026A1 (en) | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
| US6180391B1 (en) | 1998-01-28 | 2001-01-30 | Amgen Inc. | Highly efficient controlled expression of exogenous genes in e. coli |
| US6653098B1 (en) * | 1998-02-23 | 2003-11-25 | G. D. Searle & Co. | Method of producing mouse and human endostatin |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE313561T1 (de) | 1999-07-21 | 2006-01-15 | Amgen Inc | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| IL152804A0 (en) | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| CA2421588C (en) | 2000-09-05 | 2010-01-26 | Amgen Inc. | Tnf receptor-like molecules and uses thereof |
| IL157446A0 (en) | 2001-02-23 | 2004-03-28 | Immunex Corp Immunex Corp | Increased recovery of active proteins |
| US6972327B1 (en) | 2001-05-08 | 2005-12-06 | Immunex Corporation | Regeneration of chromatography material |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| ITMI20012345A1 (it) | 2001-11-08 | 2003-05-08 | Internat Ct For Genetic En Gin | Procedimento per la produzione di interferone alfa di grado terapeutico |
| SI21102A (sl) | 2001-12-19 | 2003-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika |
| AU2002345829A1 (en) | 2002-06-24 | 2004-01-06 | Dr. Reddy's Laboratories Ltd. | Process for preparing g-csf |
| US7067279B1 (en) | 2002-08-23 | 2006-06-27 | Immunex Corporation | Cell culture performance with betaine |
| BR0317538A (pt) | 2002-12-20 | 2005-11-29 | Amgen Inc | Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo |
| US7083948B1 (en) | 2002-12-24 | 2006-08-01 | Immunex Corporation | Polypeptide purification reagents and methods for their use |
| EP1449848A1 (en) | 2003-02-20 | 2004-08-25 | GBF German Research Centre for Biotechnology | Method for the production of cystine-knot proteins |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7427659B2 (en) | 2003-10-24 | 2008-09-23 | Amgen Inc. | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
| EP1711512B1 (en) | 2004-01-30 | 2012-01-11 | Amgen Inc. | Process for purifying proteins |
| AU2005222782B2 (en) | 2004-02-04 | 2010-06-17 | Ratiopharm Gmbh | Methods of refolding mammalian glycosyltransferases |
| US20050209441A1 (en) | 2004-03-22 | 2005-09-22 | Lile Jackson D | Process for promoting proper folding of human serum albumin using a human serum albumin ligand |
| CA2577690C (en) | 2004-08-19 | 2013-08-06 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
| FR2874318B1 (fr) | 2004-08-19 | 2006-11-24 | Oreal | Utilisation en cosmetique de composes polysaccharidiques amphoteres a chaine(s) polymerique(s) cationique(s) |
| DE102004041639A1 (de) | 2004-08-27 | 2006-03-02 | Bioceuticals Arzneimittel Ag | Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| US7435804B2 (en) | 2004-10-19 | 2008-10-14 | Phage Biotechnology, Inc. | Method for obtaining single chain antibodies to human interferon α2b |
| AU2005299716B2 (en) | 2004-10-22 | 2012-09-06 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| AU2005314438B2 (en) | 2004-12-10 | 2012-03-29 | Zymogenetics, Inc. | FGF18 production in prokaryotic hosts |
| JP2008528039A (ja) | 2005-01-28 | 2008-07-31 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１の均質調製物 |
| WO2006097944A2 (en) | 2005-03-17 | 2006-09-21 | Zenotech Laboratories Limited | Process for the purification of recombinant granulocyte-colony stimulating factor |
| US7344962B2 (en) | 2005-06-21 | 2008-03-18 | International Business Machines Corporation | Method of manufacturing dual orientation wafers |
| DE102005033250A1 (de) | 2005-07-15 | 2007-01-18 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von G-CSF |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US7735525B2 (en) | 2005-11-14 | 2010-06-15 | Amgen Inc. | Thermally insulated apparatus for liquid chromatographic analysis |
| WO2007075283A2 (en) | 2005-12-06 | 2007-07-05 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
| BRPI0621124A2 (pt) | 2005-12-22 | 2011-11-29 | Genentech Inc | métodos para recuperação de uma proteìna de ligação à heparina |
| US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
| US7612273B2 (en) * | 2006-03-20 | 2009-11-03 | Roland Corporation | Electronic percussion instrument |
| EP1845103B1 (en) * | 2006-04-10 | 2015-02-25 | Boehringer Ingelheim RCV GmbH & Co KG | Method for refolding a protein |
| AR062069A1 (es) | 2006-07-14 | 2008-10-15 | Genentech Inc | Replegado de proteinas recombinantes |
| EP2049821A4 (en) | 2006-07-21 | 2013-09-04 | Amgen Inc | Rupture valve |
| TW201307390A (zh) | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| WO2008097829A2 (en) | 2007-02-02 | 2008-08-14 | Neose Technologies, Inc. | Large scale production of eukaryotic n-acetylglucosaminyltransferase i in bacteria |
| WO2008096370A2 (en) | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
| WO2008100578A2 (en) | 2007-02-14 | 2008-08-21 | Amgen Inc. | Method of isolating antibodies by precipitation |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| CN102015770A (zh) | 2008-02-29 | 2011-04-13 | 特拉维夫大学拉莫特有限公司 | 免疫球蛋白组合物和生产其的方法 |
| BRPI0914251B1 (pt) | 2008-06-25 | 2022-07-19 | Novartis Ag | Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição |
| EP3366692A1 (en) | 2009-06-22 | 2018-08-29 | Amgen, Inc | Refolding proteins using a chemically controlled redox state |
| AU2010266093B2 (en) * | 2009-06-25 | 2013-06-27 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| TWI582408B (zh) | 2011-08-29 | 2017-05-11 | 安美基公司 | 用於非破壞性檢測－流體中未溶解粒子之方法及裝置 |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US20160038588A1 (en) | 2013-03-15 | 2016-02-11 | Amgen Inc. | Myostatin Antagonism in Human Subjects |
| US9632095B2 (en) | 2014-12-01 | 2017-04-25 | University Of Delaware | Device and method for determining reaction kinetics |
| US9704239B1 (en) | 2016-09-02 | 2017-07-11 | Amgen Inc. | Video trigger synchronization for improved particle detection in a vessel |
-
2010
- 2010-06-21 EP EP18167168.6A patent/EP3366692A1/en active Pending
- 2010-06-21 US US12/820,087 patent/US8952138B2/en active Active
- 2010-06-21 BR BRPI1011940A patent/BRPI1011940B8/pt active IP Right Grant
- 2010-06-21 KR KR1020127001716A patent/KR101741859B1/ko active Active
- 2010-06-21 AU AU2010270986A patent/AU2010270986B2/en active Active
- 2010-06-21 SG SG2011095411A patent/SG176963A1/en unknown
- 2010-06-21 CA CA2765881A patent/CA2765881C/en active Active
- 2010-06-21 WO PCT/US2010/039390 patent/WO2011005488A1/en not_active Ceased
- 2010-06-21 EP EP10747092.4A patent/EP2445923B1/en active Active
- 2010-06-21 CN CN201080028756.7A patent/CN102482321B/zh active Active
- 2010-06-21 MX MX2011013898A patent/MX2011013898A/es active IP Right Grant
- 2010-06-21 JP JP2012517634A patent/JP5808323B2/ja active Active
- 2010-06-21 EA EA201270015A patent/EA020621B1/ru not_active IP Right Cessation
-
2011
- 2011-12-13 IL IL216954A patent/IL216954A/en active IP Right Grant
- 2011-12-22 CL CL2011003278A patent/CL2011003278A1/es unknown
-
2012
- 2012-01-20 ZA ZA2012/00512A patent/ZA201200512B/en unknown
-
2015
- 2015-01-30 US US14/611,037 patent/US20150315232A1/en not_active Abandoned
- 2015-07-07 US US14/793,590 patent/US20150329586A1/en not_active Abandoned
- 2015-09-07 JP JP2015175422A patent/JP6026608B2/ja active Active
-
2017
- 2017-02-01 US US15/422,327 patent/US9856287B2/en active Active
-
2018
- 2018-02-06 US US15/889,559 patent/US12269843B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011940B8 (pt) | método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero | |
| BR112015022971A2 (pt) | métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes | |
| AR088513A1 (es) | Inmunoenlazantes dirigidos contra esclerostina | |
| PE20081655A1 (es) | Medios racionalmente disenados para cultivo celular | |
| BR112016023304A2 (pt) | célula hospedeira recombinante engendrada para superexpressar proteínas auxiliares | |
| BR112012028805A2 (pt) | composições de endorribonuclease e métodos de uso das mesmas. | |
| BR112015022322A2 (pt) | sistemas e métodos para detecção de células com o uso de partículas de transdução projetadas | |
| CL2007001488A1 (es) | Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina. | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| CL2008000935A1 (es) | Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige. | |
| CO6470854A2 (es) | Variantes de celulasa con expresión, actividad y/o estabilidad mejoradas, y uso de las mismas | |
| BR122019022434B8 (pt) | método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular | |
| CL2008002085A1 (es) | Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b | |
| MX2020003168A (es) | Pirimidinas modificadas en la posicion 5 y su uso. | |
| CL2013002361A1 (es) | Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína; | |
| BR112014006244A2 (pt) | microrganismos e métodos para produzir alcenos | |
| BR112013026883A2 (pt) | Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica | |
| BR112015001620A2 (pt) | composição de meio de cultura, e método para cultivo de célula ou tecido usando-se dita composição | |
| MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
| UY33802A (es) | Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja | |
| BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
| BR112014006511A2 (pt) | atividade de dnase endógena para reduzir teor de dna | |
| AR092879A1 (es) | Proteinas de fusion de g3p como agentes de union a amiloide | |
| BR112013021836A2 (pt) | plantas que possuem características relativas a rendimento aprimoradas e métodos de sua produção | |
| EA201190285A1 (ru) | Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2564 DE 27/02/2020 POR TER SIDO INDEVIDA. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/07/2021, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2637 DE 20/07/2021 QUANTO AO PRAZO DE VALIDADE. |